Valuation: Viyash Scientific Limited

Market Cap 116B 1.22B 1.06B 990M 903M 1.7B 1.73B 11.66B 4.55B 58.21B 4.57B 4.48B 194B P/E 2027 *
34.8x
P/E 2028 * 21.7x
Enterprise Value 116B 1.22B 1.06B 990M 903M 1.7B 1.73B 11.66B 4.55B 58.21B 4.57B 4.48B 194B EV / Sales 2027 *
3x
EV / Sales 2028 * 2.6x
Free-Float
32.71%
Yield 2027 *
-
Yield 2028 * -
1 day+1.33%
1 week-2.36%
Current month+5.71%
1 month-6.26%
3 months+18.66%
6 months+23.36%
Current year+28.01%
1 week 253.7
Extreme 253.7
281.05
1 month 248.05
Extreme 248.05
284.15
Current year 178.4
Extreme 178.4
297.9
1 year 167.5
Extreme 167.5
297.9
3 years 86.03
Extreme 86.03
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 15/12/2025
Director of Finance/CFO - 31/12/2025
Chief Tech/Sci/R&D Officer - 04/02/2026
Director TitleAgeSince
Chairman 78 -
Director/Board Member 66 24/08/2020
Director/Board Member 57 10/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
+1.33%-2.36%+55.27%+190.79% 1.2B
-0.92%+1.43%+83.05%+128.86% 1,088B
+0.47%+1.98%+50.26%+50.75% 629B
+0.83%+2.85%+24.49%+64.82% 440B
-0.88%-0.66%+45.09%+36.64% 359B
-0.37%-1.15%+26.89%+36.31% 291B
+0.05%-1.20%+2.31%+6.15% 245B
+0.40%+3.21%+44.42%+59.17% 225B
-0.42%+1.58%-8.48%-51.94% 204B
+1.67%+5.56%+14.98%+72.68% 168B
Average +0.22%+1.10%+33.83%+59.42% 365.04B
Weighted average by Cap. -0.13%+1.46%+46.06%+66.01%

Financials

2027 *2028 *
Net sales 38.82B 407M 353M 331M 301M 567M 576M 3.89B 1.52B 19.43B 1.53B 1.49B 64.83B 44.68B 468M 406M 380M 347M 653M 663M 4.48B 1.75B 22.37B 1.76B 1.72B 74.62B
Net income 3.62B 37.97M 32.91M 30.85M 28.13M 52.93M 53.78M 363M 142M 1.81B 143M 139M 6.05B 5.69B 59.6M 51.66M 48.43M 44.16M 83.08M 84.41M 570M 223M 2.85B 224M 219M 9.5B
Net Debt - -
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
13/08/26 ₹266.45 +1.33% 237,526
12/08/26 ₹262.95 +0.57% 137,573
11/08/26 ₹261.45 -4.51% 368,524
10/08/26 ₹273.80 -1.19% 79,027
07/08/26 ₹277.10 +1.54% 96,153
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
266.45INR
Average target price
319.75INR
Spread / Average Target
+20.00%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIYASH Stock